CMTA Clementia Pharmaceuticals Inc.

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2019

 

Commission File Number: 001-38177

 

 

Clementia Pharmaceuticals Inc.

(Translation of registrant ’ s name into English)

 

 

4150 Sainte-Catherine Street West, Suite 550
Montreal, Quebec, Canada H3Z 2Y5
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F  x                  Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

DOCUMENTS FURNISHED AS PART OF THIS FORM 6-K

 

A press release dated March 6, 2019.

 

Support and Voting Agreement dated March 2, 2019, between BDC Capital Inc., 11188291 Canada Inc. and Ipsen S.A.

 

Support and Voting Agreement dated March 4, 2019, between New Enterprise Associates 15, L.P., 11188291 Canada Inc. and Ipsen S.A.

 

Exhibits

 

99.1 – Press Release dated March 6, 2019

 

99.2 – Support and Voting Agreement dated March 2, 2019, between BDC Capital Inc., 11188291 Canada Inc. and Ipsen S.A.

 

99.3 – Support and Voting Agreement dated March 4, 2019, between New Enterprise Associates 15, L.P., 11188291 Canada Inc. and Ipsen S.A.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Clementia Pharmaceuticals Inc.
	(Registrant)
Date: March 6, 2019	By:	/s/ Clarissa Desjardins
		Clarissa Desjardins
		Chief Executive Officer